Interim RAINIER data show povetacicept reduced proteinuria by 52.0% and resolved hematuria in 85% of patients at week 36, ahead of a November PDUFA date.
|Articles|September 16, 2008
- March31 2003
- Volume 10
- Issue 6
DID YOU KNOW…
Advertisement
(American Demographics, 2003)
38%—Percentage of Americanswho have had laser eye surgery.
(American Demographics, 2003)
20%—Percentage of Americanswho have had liposuction.
(American Demographics, 2003)
12%—Percentage of Americanswho have had a face-lift.
(American Demographics, 2003)
7%—Percentage of Americanswho have had a nose job.
(Harris Poll, 2003)
64%—Percentage of Americanswho consider major Medicarereforms to be very needed.
(US CensusBureau, 2003)
$47.37 —Average monthly cellphone bill in America.
(US Census Bureau, 2003)
44%—Percentage of Americanswho do volunteer work eachyear.
(USA Today, 2003)
4%—Percentage of time a PGATour player 3-putts on a golfhole.
(USA Today, 2003)
26%—Percentage of time a PGATour player 1-putts on a golfhole.
(US News &World Report, 2003)
58%—Percentage of oil consumedin the United States thatis foreign- produced.
Articles in this issue
about 18 years ago
WAR AND WALL STREETabout 18 years ago
THE 529 FACTSabout 18 years ago
A WILL THAT WORKSabout 18 years ago
WALL STREET WOESabout 18 years ago
FINANCIAL PLANNING KEYabout 18 years ago
MIXED SIGNALSabout 18 years ago
PAPERWORK REDUCTIONabout 18 years ago
SHRINKING GIFTSabout 18 years ago
Medicare Cuts Deniedabout 18 years ago
A WILL ONLINEAdvertisement
Related to this article
Interim I CAN data show ravulizumab reduced proteinuria by 43.4% vs placebo at week 34, supporting its FDA accelerated approval in IgA nephropathy.
Lorundrostat cut systolic BP by 9.6 mm Hg and UACR by 52.2% vs placebo in participants with CKD and uncontrolled hypertension in Launch-HTN.
The ENRICH-AF trial ultimately did not demonstrate edoxaban’s efficacy, highlighting the need for further stroke prevention strategies for this patient population.
Final TELIGAN data show telitacicept cut confirmed 30% eGFR decline by 89% and reduced proteinuria by 60.7% vs placebo over 2 years in IgA nephropathy.
Participants described how payer requirements and documentation of steroid exposure shape biologic access.
In TRANSCEND-CKD, retatrutide reduced UACR by 49.2% vs placebo and lowered intraglomerular pressure and kidney fat without changing measured GFR at 24 weeks.
Ravulizumab cut proteinuria 43.4% vs placebo at week 34 in I CAN, making it the first C5 inhibitor approved for IgA nephropathy under accelerated approval.
Advertisement
Advertisement
Trending on HCPLive
1
Retatrutide Lowers Albuminuria, Glomerular Pressure in Obesity and CKD
2
AD109 Yields Numerically Greater OSA Improvements in Postmenopausal Women
3
Sleeve Gastrectomy Improves Heart, Kidney MRI Markers in Youth-Onset T2D
4
TELIGAN: Telitacicept Preserves eGFR Through 2 Years in IgA Nephropathy
5